NANJING , China , Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products.
The study, which focuses on how mutant IDH1 inhibition activates tumor immunity by inducing double-stranded DNA (dsDNA) sensing, utilized Vazyme's advanced tools to achieve compelling research results. These findings are driving progress in life science, fostering transformative changes and innovations, and advancing both academic research and the broader medical sector. The research, led by the cancer research team at Harvard Medical School and Massachusetts General Hospital and the Broad Institute of MIT and Harvard , was authored by Dr.
Meng-Ju Wu and his team. Reporting in Science , their paper, "Mutant IDH1 Inhibition Induces dsDNA Sensing to Activate Tumor Immunity", reveals how mutant IDH1 inhibition activates tumor immunity by inducing dsDNA sensing. Research has found that mIDH1 inhibitors cause DNA demethylation, which reactivates dormant viral genes embedded in the genome from ancient infections, subsequently activating cGAS, a protein responsible for detecting these viral elements.
This reactivation triggers a viral mimicry response, effectively mobilizing the immune system to attack and destroy tumor cells. In preclinical models, mIDH1 inhibition led to the rapid recruitment of CD8 + T cells and a strong anti-tumor immune response. These f.